Results 251 to 260 of about 433,923 (290)
Some of the next articles are maybe not open access.
Immunotherapy for pancreatic ductal adenocarcinoma
Journal of Surgical Oncology, 2021AbstractPancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors.
Eileen Carpenter +7 more
openaire +2 more sources
Microbiome and pancreatic ductal adenocarcinoma
Clinics and Research in Hepatology and Gastroenterology, 2021Pancreatic ductal adenocarcinoma (PDAC) incidence and related-deaths are increasing worldwide. PDAC is characterized by poor prognosis due to late diagnosis, high metastatic capacity and resistance to therapy. This is partially due to its specific microenvironment, where the stroma is prominent over tumor cells. Besides the oral and gut microbiota, the
Annemilaï Tijeras-Raballand +5 more
openaire +2 more sources
Hypoxia and pancreatic ductal adenocarcinoma
Cancer Letters, 2020Chemotherapy and immunotherapy for pancreatic ductal adenocarcinoma (PDAC) have limited success. One reason for this is thought to be the cancer microenvironment surrounding PDAC. Hypoxia is a feature of the cancer microenvironment. Under hypoxia, different various molecules and signaling pathways are activated compared with normoxia.
Akio, Yamasaki +2 more
openaire +2 more sources
Surgical Treatment of Pancreatic Ductal Adenocarcinoma
Cancers, 2021 This special issue, “Surgical Treatment of Pancreatic Ductal Adenocarcinoma” contains 13 articles (five original articles, five reviews, and three systematic reviews/meta-analyses) authored by international leaders and surgeons who treat patients with ...
Kongyuan Wei, Thilo Hackert
exaly +2 more sources
Genomics of pancreatic ductal adenocarcinoma
Hepatobiliary & Pancreatic Diseases International, 2014Pancreatic cancer is one of the worst prognostic cancers because of the late diagnosis and the absence of effective treatment. Within all subtypes of this disease, ductal adenocarcinoma has the shortest survival time. In recent years, global genomics profiling allowed the identification of hundreds of genes that are perturbed in pancreatic cancer.
Christian, Pilarsky, Robert, Grutzmann
openaire +2 more sources
Biomarkers in pancreatic ductal adenocarcinoma
Clinical and Translational Oncology, 2017Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego +4 more
openaire +2 more sources
Pancreatic Ductal Adenocarcinoma and Its Variants
Surgical Pathology Clinics, 2016 Pancreatic cancer represents the seventh leading cause of cancer death in the world, responsible for more than 300,000 deaths per year. The most common tumor type among pancreatic cancers is pancreatic ductal adenocarcinoma, an infiltrating neoplasm with
Aldo Scarpa +2 more
exaly +2 more sources
Surgery for pancreatic ductal adenocarcinoma
Clinical and Translational Oncology, 2017Surgical resection is the only potentially curative option in the treatment of pancreatic ductal adenocarcinoma. Preoperative radiological imaging allows to rule out the presence of metastases. Three resectability categories are established based on the radiological findings depending on the degree of contact between the tumor and the blood vessels ...
R. Vera +5 more
openaire +2 more sources